Systemic lupus erythematosus activity and beta two microglobulin levels
Keywords:
Lupus erythematosus, systemic, beta 2-microglobulin, Inflammation, Blood sedimentation, Acute-phase reactionAbstract
CONTEXT AND OBJECTIVE: Systemic lupus erythematosus (SLE) is an autoimmune disease with a cyclical clinical course. Evaluation of the clinical activity of this disease is important for choosing the correct treatment. The objective of this study was to analyze the value of beta-2 microglobulin (β2M) serum levels in determining SLE clinical activity. DESIGN AND SETTING: Cross-sectional analytical study conducted at the rheumatology outpatient clinic of a private university hospital. METHODS: 129 SLE patients were studied regarding disease activity using SLEDAI (SLE Disease Activity Index) and cumulative damage using SLICC ACR (SLE International Collaborating Clinics/American College of Rheumatology Damage Index for SLE). At the same time, the β2M serum level, ESR (erythrocyte sedimentation rate), anti-dsDNA (anti-double-stranded DNA) and C3 and C4 complement fractions were determined. RESULTS: β2M levels correlated positively with SLEDAI (P = 0.02) and ESR (P = 0.0009) and negatively with C3 (P = 0.007). Patients who were positive for anti-dsDNA had higher β2M serum levels (P = 0.009). CONCLUSION: β2M levels are elevated in SLE patients with active disease.
Downloads
References
Suh CH, Jeing YS, Park HC, et al. Risk factors for infection and role of C-reactive protein in Korean patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2001;19(2):191-4.
Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for clinical assessment of disease activity on systemic lupus erythematosus. Arthritis Rheum. 1989;32(9):1107-18.
McPhee CG, Sproule TJ, Shin DM, et al. MHC class I family proteins retard systemic lupus erythematosus autoimmunity and B cell lymphomagenesis. J Immunol. 2011;187(9):4695-704.
Kim HA, Jeon JY, Yoon JM, Suh CH. Beta 2-microglobulin can be a disease activity marker in systemic lupus erythematosus. Am J Med Sci. 2010;339(4):337-40.
Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-7.
Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol. 1996;35(3):248-54.
Xie J, Wang Y, Freeman ME 3rd, Barlogie B, Yi Q. Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood. 2003;101(10):4005-12.
Evrin PE, Ström T. Beta 2-microglobulin and its binding activity in serum from patients with SLE. Ann Rheum Dis. 1984;43(2):267-74.
Walters MT, Stevenson FK, Goswami R, Smith JL, Cawley MI. Comparison of serum and synovial fluid concentrations of beta 2-microglobulin and C reactive protein in relation to clinical disease activity and synovial inflammation in rheumatoid arthritis. Ann Rheum Dis. 1989;48(11):905-11.
Chan OT, Paliwal V, McNiff JM, et al. Deficiency in beta(2)-microglobulin, but not CD1, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRL-Fas(lpr) mice: an example of disease regulation at the organ level. J Immunol. 2001;167(5):2985-90.
Hermansen ML, Hummelshøj L, Lundsgaard D, et al. Increased serum β2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosus patients. Lupus. 2012;21(10):1098-104.
Falk RJ, Schur PH, Appel GB. Clinical features and therapy of membranous lupus nephritis. Uptodate.com. Available from: http:// www.uptodate.com/contents/clinical-features-and-therapy-of- membranous-lupus-nephritis. Accessed in 2013 (Sep 4).
Sun HO, Hu WX, Xie HL, et al. Long-term outcome of Chinese patients with membranous lupus nephropathy. Lupus. 2008;17(1):56-61.
